secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001178670-25-000050
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q1 product rev $469M (+28% YoY); AMVUTTRA approved for ATTR-CM; guides FY25 $2.05-2.25B
--------------------------------------------------------------------------------

- Q1 total revenues $594M, up 20% YoY; GAAP operating income $18M vs loss of $43M in Q1 2024.
- Q1 global net product revenues $469M, 28% growth YoY; hATTR-PN franchise grew 36%.
- AMVUTTRA (vutrisiran) received FDA approval for ATTR-CM; launch underway with early progress.
- Qfitlia (fitusiran) approved by FDA for hemophilia A/B, sixth Alnylam-discovered RNAi therapeutic.
- Reiterated FY2025 combined net product revenue guidance of $2.05B-$2.25B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000050/0001178670-25-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867025000050/alny-20250501.htm
  HTML page:      https://secwatch.observer/filing/0001178670-25-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer